Expression genomics and drug development: Towards predictive pharmacology

Briefings in Functional Genomics and Proteomics

Volumn 3, Issue 4, 2005, Pages 303-321

  Liu, Edison T ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

cDNAs; Drug effects; Expression signatures; Gene regulation; Transcription

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; FLT3 LIGAND; FLUOROURACIL; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; POLO LIKE KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR; T CELL FACTOR PROTEIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ARTICLE; CHROMATIN; DATA BASE; DNA MICROARRAY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EXPRESSED SEQUENCE TAG; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; GENOMICS; HUMAN; IMMUNOPRECIPITATION; INFORMATION PROCESSING; LUNG ADENOCARCINOMA; MEDICAL TECHNOLOGY; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROTEIN MICROARRAY; SERIAL ANALYSIS OF GENE EXPRESSION; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; CHROMATIN IMMUNOPRECIPITATION; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA, COMPLEMENTARY; DRUG DESIGN; EXPRESSED SEQUENCE TAGS; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; MUTATION; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 16344364326     PISSN: 14739550     EISSN: None     Source Type: Journal    
DOI: 10.1093/bfgp/3.4.303     Document Type: Article

References (92)

1. Davidson, E. H., Rast, J. P., Oliveri, P. et al. (2002), 'A provisional regulatory gene network for specification of endomesoderm in the sea urchin embryo', Dev. Biol., Vol. 246, pp. 162-190.
2. Davidson, E. H., Rast, J. P., Oliveri, P. et al. (2002), 'A genomic regulatory network for development', Science, Vol. 295, pp. 1669-1678.
3. Bolouri, H. and Davidson, E. H. (2003), 'Transcriptional regulatory cascades in development: Initial rates, not steady state, determine network kinetics', Proc. Natl. Acad. Sci. USA, Vol.100, pp. 9371-9376.
4. Futreal, P. A., Coin, L., Marshall, M. et al. (2004), 'A census of human cancer genes', Nat. Rev., Vol. 4, pp. 177-183.
5. Lipshutz, R. J., Fodor, S. P. A., Gingeras, T. R. and Lockhart, D. J. (1999), 'High density synthetic oligonucleotide arrays', Nat. Genet., Vol. 21, pp. 20-24.
6. Eisen, M. B. and Brown, P. O. (1999), 'DNA arrays for analysis of gene expression', in Weissman, S. M. (ed.), 'Methods in Enzymology: cDNA Preparation and Characterization', Vol. 303, Academic Press, San Diego, CA, pp.179-205.
7. Harrington, C. A., Rosenow, C. and Retief, J. (2000), 'Monitoring gene expression using DNA microarrays', Curr. Opin. Microbiol., Vol. 3, pp. 285-291.
8. Miller, L. D., Long, P. M., Wong, L. et al. (2002), 'Optimal gene expression analysis by microarrays', Cancer Cell, Vol. 2, pp. 353-361.
9. Stears, R. L., Martinsky, T. and Schena, M. (2003), 'Trends in microarray analysis', Nat. Med., Vol. 9, pp. 140-145.
10. Ruan, Y., Le Ber, P., Ng, H. H. and Liu, E. T. (2004), 'Interrogating the transcriptome', Trends Biotechnol., Vol. 22, pp. 23-30.
11. Brenner, S. and Livak, K. J. (1989), 'DNA fingerprinting by sampled sequencing', Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 8902-8906.
12. Kapranov, P., Cawley, S. E., Drenkow, J. et al. (2002), 'Large-scale transcriptional activity in chromosomes 21 and 22', Science, Vol. 296, pp. 916-919.
13. Cawley, S., Bekiranov, S., Ng, H. H. et al. (2004), 'Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs', Cell, Vol. 116, pp. 499-509.
14. Johnson, J. M., Castle, J., Garrett-Engele, P. et al. (2003), 'Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays', Science, Vol. 302, pp. 2141-2144.
15. Wei, C. L., Ng, P., Chiu, K. P. et al. (2004), '5′ Long serial analysis of gene expression (LongSAGE) and 3′ LongSAGE for transcriptome characterization and genome annotation', Proc. Natl. Acad. Sci. USA, Vol. 101, pp. 11701-11706.
16. Druker, B. J. (2004), 'Imatinib as a paradigm of targeted therapies', Adv. Cancer Res., Vol. 91, pp. 1-30.
17. Liu, E. T., Sandler, D., Neubauer, A. et al. (1991), 'Clinical and etiologic importance of mutant ras genes in adult acute myeloid leukemia (AML)', Blood, Vol. 78 (Suppl. 1), p. 1340.
18. Koo, H. M., McWilliams, M. J., Alvord, W. G. and Vande Woude, G. F. (1999), 'Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine', Cancer Res., Vol. 59, pp. 6057-6062.
19. Koo, H. M., Gray-Goodrich, M., Kohlhagen, G. et al. (1999), 'The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis', J. Natl. Cancer Inst. Vol. 91, pp. 236-244.
20. Sattler, M., Scheijen, B., Weisberg, E. and Griffin, J. D. (2003), 'Mutated tyrosine kinases as therapeutic targets in myeloid leukemias', Adv. Exp. Med. Biol., Vol. 532, pp. 121-140.
21. O'Farrell, A. M., Yuen, H. A., Smolich, B. et al. (2004), 'Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukaemia', Leuk. Res., Vol. 28, pp. 679-689.
22. O'Farrell, A. M., Abrams, T. J., Yuen, H. A. et al. (2003), 'SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo', Blood, Vol. 101, pp. 3597-3605.
23. Parsons, R., Myeroff, L. L., Liu, B. et al. (1995), 'Microsatellite instability and mutations of the transforming growth factor betatype II receptor gene in colorectal cancer', Cancer Res. Vol. 55, pp. 5548-5550.
24. Davies, H., Bignell, G. R., Cox, C. et al. (2002), 'Mutations of the BRAF gene in human cancer', Nature, Vol. 417, pp. 949-954.
25. Wilhelm, S. M., Carter, C., Tang, L. et al. (2004), 'BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis', Cancer Res., Vol. 64, pp. 7099-7109.
26. Paez, J. G., Janne, P. A., Lee, J. C., et al. (2004), 'EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy', Science, Vol. 304, pp. 1497-1500.
27. Herbst, R. S., Fukuoka, M. and Baselga, J. (2004), 'Timeline: Gefitinib - a novel targeted approach to treating cancer', Nat. Rev. Cancer, Vol. 4, pp. 956-965.
28. Stephens, P., Hunter, C., Bignell, G. et al. (2004), 'Lung cancer: Intragenic ERBB2 kinase mutations in tumours', Nature Vol. 431, pp. 525-526.
29. Wang, Z., Shen, D., Parsons, D. W. et al. (2004), 'Mutational analysis of the tyrosine phosphatome in colorectal cancers', Science, Vol. 304, pp. 1164-1166.
30. Hughes, T. R., Marton, M. J., Jones, A. R. et al. (2000), 'Functional discovery via a compendium of expression profiles', Cell, Vol. 102, pp. 109-126.
31. Miller, L. D., Park, K. S., Guo, Q. M. et al. (2001), 'Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation', Mol. Cell. Biol., Vol. 21, pp. 6626-6639.
32. Guo, Q. M., Malek, R. L., Kim, S. et al. (2000), 'Identification of c-myc responsive genes using rat cDNA microarray', Cancer Res., Vol. 60, pp. 5922-5928.
33. Iritani, B. M. and Eisenman, R. N. (1999), c-Myc enhances protein synthesis and cell size during B lymphocyte development', Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 13180-13185.
34. Aprelikova, O., Pace, A. J., Fang, B. et al. (2001), 'BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells', J. Biol. Chem., Vol. 276, pp. 25647-25650.
35. Kho, P. S., Wang, Z., Zhuang, L. et al. (2004), 'p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis', J. Biol. Chem., Vol. 279, pp. 21183-21192.
36. Majumder, P. K., Febbo, P. G., Bikoff, R. et al. (2004), 'mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways', Nat. Med., Vol. 10, pp. 594-601.
37. Chen, C. D., Welsbie, D. S., Tran, C. et al. (2004), 'Molecular determinants of resistance to antiandrogen therapy', Nat. Med., Vol. 10, pp. 33-39.
38. Frasor, J., Danes, J. M., Komm, B. et al. (2003), 'Profiling of estrogen up- and downregulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype', Endocrinology Vol. 144, pp. 4562-4574.
39. Coser, K. R., Chesnes, J., Hur, J. et al. (2003), 'Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray', Proc. Natl. Acad. Sci. USA, Vol. 100, pp. 13994-13999.
40. Lin, C. Y., Strom, A., Vega, V. B. et al. (2004), 'Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells', Genome Biol., Vol. 5, p. R66.
41. Bajic, V. B., Tan, S. L., Chong, A. et al. (2003), 'Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes', Nucleic Acids Res., Vol. 31, pp. 3605-3607.
42. Desai, K. V., Xiao, N., Wang, W. et al. (2003), 'Initiating oncogenic event determines gene-expression patterns of human breast cancer models', Proc. Natl. Acad. Sci. USA, Vol. 99, pp. 6967-6972.
43. Jazaeri, A. A., Yee, C. J., Sotiriou, C. et al. (2002), 'Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers', J. Natl. Cancer Inst., Vol. 94, pp. 990-1000.
44. Hedenfalk, I., Duggan, D., Chen, Y. et al. (2001), 'Gene-expression profiles in hereditary breast cancer', N. Engl. J. Med., Vol. 344, pp. 539-548.
45. Ganesan, S., Silver, D. P., Greenberg, R. A. et al. (2002), 'BRCA1 supports XIST RNA concentration on the inactive X chromosome', Cell, Vol. 111, pp. 393-405.
46. Jazaeri, A. A., Chandramouli, G. V., Aprelikova, O. et al. (2004), 'BRCA1-mediated repression of select X chromosome genes', J. Transl. Med., Vol. 2, p. 32.
47. Ferrando, A. A., Neuberg, D. S., Staunton, J. et al. (2002), 'Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukaemia', Cancer Cell, Vol. 1, pp. 75-87.
48. Ferrando, A. A., Neuberg, D. S., Dodge, R. K. et al. (2004), 'Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia', Lancet, Vol. 363, pp. 535-536.
49. Relling, M. V., Hancock, M. L., Rivera, G. K. et al. (1999), 'Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus', J. Natl. Cancer Inst., Vol. 91, pp. 2001-2008.
50. Krynetski, E. and Evans, W. E. (2003), 'Drug methylation in cancer therapy: Lessons from the TPMT polymorphism', Oncogene, Vol. 22, pp. 7403-7413.
51. Liu, E. T. (2001), 'Molecular Markers in cancer therapy: Evolution of a concept', in Mendelsohn, J., Howley, P., Israel, M. and Liotta, L. (eds), 'Molecular Basis of Cancer', 2nd edn, W. B. Saunders, Philadelphia.
52. Perou, C. M., Sorlie, T., Eisen, M. B. et al. (2000), 'Molecular portraits of human breast tumours', Nature, Vol. 406, pp. 747-752.
53. Sorlie, T., Perou, C. M., Tibshirani, R. et al. (2001), 'Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications', Proc. Natl. Acad. Sci. USA, Vol. 98, pp. 10869-10874.
54. Sotiriou, C., Neo, S. Y., McShane, L. M. et al. (2003), 'Breast cancer classification and prognosis based on gene expression profiles from a population-based study', Proc. Natl. Acad. Sci. USA Vol. 100, pp. 10393-10398.
55. Sorlie, T., Tibshirani, R., Parker, J. et al. (2003), 'Repeated observation of breast tumor subtypes in independent gene expression data sets', Proc. Natl. Acad. Sci. USA, Vol. 100, pp. 8418-8423.
56. van't Veer, L. J., Dai, H., van de Vijver, M. J. et al. (2002), 'Gene expression profiling predicts clinical outcome of breast cancer', Nature, Vol. 415, pp. 530-536.
57. van de Vijver, M. J., He, Y. D., van't Veer, L. J. et al. (2002), 'A gene-expression signature as a predictor of survival in breast cancer', N. Engl. J. Med., Vol. 347, pp. 1999-2009.
58. Garber, K. (2004), 'Gene expression tests foretell breast cancer's future', Science, Vol. 303, pp. 1754-1755.
59. Singh, D., Febbo, P. G., Ross, K. et al. (2002), 'Gene expression correlates of clinical prostate cancer behaviour', Cancer Cell, Vol. 1, pp. 203-209.
60. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D. et al. (2001), 'Delineation of prognostic biomarkers in prostate cancer', Nature, Vol. 412, pp. 822-826.
61. Varambally, S., Dhanasekaran, S. M., Zhou, M. et al. (2002), 'The polycomb group protein EZH2 is involved in progression of prostate cancer', Nature, Vol. 419, pp. 624-629.
62. Staudt, L. M. (2002), 'It's ALL in the diagnosis', Cancer Cell, Vol. 1, pp. 109-110.
63. Yeoh, E. J., Ross, M. E., Shurtleff, S. A. et al. (2002), 'Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling', Cancer Cell, Vol. 1, pp. 133-143.
64. Ferrando, A. A., Neuberg, D. S., Staunton, J. et al. (2002), 'Look AT. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukaemia', Cancer Cell, Vol. 1, pp. 75-87.
65. Bullinger, L., Dohner, K., Bair, E. et al. (2004), 'Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukaemia', N. Engl. J. Med., Vol. 350, pp. 1605-1616.
66. Valk, P. J., Verhaak, R. G., Beijen, M. A. et al. (2004), 'Prognosticatly useful gene-expression profiles in acute myeloid leukaemia', N. Engl. J. Med., Vol. 350, pp. 1617-1628.
67. Alizadeh, A. A., Eisen, M. B., Davis, R. E. et al. (2000), 'Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling', Nature, Vol. 403, pp. 503-511.
68. Rosenwald, A., Wright, G., Chan, W. C. et al. (2002), 'Lymphoma/leukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma', N. Engl. J. Med., Vol. 346, pp. 1937-1947.
69. Shipp, M. A., Ross, K. N., Tamayo, P. et al. (2002), 'Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning', Nat. Med., Vol. 8, pp. 68-74.
70. Wheeler, G. D. (2003), 'Ruboxistaurin (Eli Lilly)' I Drugs, Vol. 6, pp. 159-163.
71. Teicher, B. A., Menon, K., Alvarez, E. et al. (2002), 'Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts', Invest. New Drugs, Vol. 20, pp. 241-251.
72. Teicher, B. A., Alvarez, E., Menon, K. et al. (2002), 'Antiangiogenic effects of a protein kinase C beta-selective small molecule', Cancer Chemother. Pharmacol., Vol. 49, pp. 69-77.
73. Scherf, U., Ross, D. T., Waltham, M., et al. (2000), 'A gene expression database for the molecular pharmacology of cancer', Nat. Genet., Vol. 24, pp. 236-244.
74. Ross, D. T., Scherf, U., Eisen, M. B. et al. (2000), 'Systematic variation in gene expression patterns in human cancer cell lines', Nat. Genet., Vol. 24, pp. 227-235.
75. Staunton, J. E., Slonim, D. K., Coller, H. A. et al. (2001), 'Chemosensitivity prediction by transcriptional profiling', Proc. Natl. Acad. Sci. USA, Vol. 98, pp. 10787-10792.
76. Kikuchi, T., Daigo, Y., Katagiri, T. et al. (2003), 'Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs', Oncogene, Vol. 22, pp. 2192-2205.
77. Holleman, A., Cheok, M. H., den Boer, M. L. et al. (2004), 'Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment', N. Engl. J. Med., Vol. 351, pp. 533-542.
78. Sotiriou, C., Powles, T. J., Dowsett, M. et al. (2002), 'Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer', Breast Cancer Res., Vol. 4, p. R3.
79. Cheok, M. H., Yang, W., Pui, C. H. et al. (2003), 'Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells', Nat. Genet., Vol. 34, pp. 85-90.
80. Bain, M. R., Nicoletti, M. I., Alkharouf, N. W. et al. (2004), 'Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts', Mol. Cancer Ther., Vol. 3, pp. 111-121.
81. Evans, W. E. and Relling, M. V. (2004), 'Moving towards individualized medicine with pharmacogenomics', Nature, Vol. 429, pp. 464-468.
82. Hunter, K. W. (2003), 'Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination', Cancer Lett., Vol. 200, pp. 97-105.
83. Qiu, T. H., Chandramouli, G. V., Hunter, K. W. et al. (2004), 'Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease', Cancer Res., Vol. 64, pp. 5973-5981.
84. Ramaswamy, S., Ross, K. N., Lander, E. S. and Golub, T. R. (2003), 'A molecular signature of metastasis in primary solid tumors', Nat. Genet., Vol. 33, pp. 49-54.
85. Chuang, Y. Y., Chen, Y., Gadisetti, C. et al. (2002), 'Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells', Cancer Res., Vol. 62, pp. 6246-6254.
86. de Longueville, F., Bertholet, V. and Remacle, J. (2004), 'DNA microarrays as a tool in toxicogenomics', Comb. Chem. High Throughput Screen, Vol. 7, pp. 207-211.
87. Suter, L., Babiss, L. E., Wheeldon, E. B. (2004), 'Toxicogenomics in predictive toxicology in drug development', Chem. Biol., Vol. 11, pp. 161-171.
88. Burczynski, M. E., McMillian, M., Ciervo, J. et al. (2000), 'Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells', Toxicol. Sci., Vol. 58, pp. 399-415.
89. Jessen, B. A., Mullins, J. S., De Peyster, A. and Stevens, G. J. (2003), 'Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression', Toxicol. Sci. Vol. 75, pp. 208-222.
90. de Longueville, F., Atienzar, F. A., Marcq, L. et al. (2003), 'Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes', Toxicol. Sci., Vol. 75, pp. 378-392.
91. Kier, L. D., Neft, R., Tang, L. et al. (2004), 'Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro', Mutat. Res., Vol. 549, pp. 101-113.
92. Rieger, K. E., Hong, W. J., Tusher, V. G. et al. (2004), 'Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage', Proc. Natl. Acad. Sci. USA Vol. 101, pp. 6635-6640.